SCHEMBL4644874

SCHEMBL4644874

COCCOc1cc(OC(=O)Oc2ccc(C(C)(C)C)c(OCCOC)c2)ccc1C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 10/20 0.38
LMNA P02545 3/20 0.38
ALDH1A1 P00352 4/20 0.38
GAA P10253 3/20 0.38
KMT2A Q03164 2/20 0.37
MAPK1 P28482 3/20 0.36
EPHX2 P34913 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
MEN1 O00255 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.36
ELANE P08246 1/20 0.36
MDH1 P40925 1/20 0.36
MDH2 P40926 1/20 0.36
LPAR1 Q92633 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4640469 0.92 ELANE (0.44) HTTL3MBTL1KDM4ELMNAALDH1A1
SCHEMBL4644879 0.90 KDM4E (0.40) HTTL3MBTL1KDM4ELMNAALDH1A1
SCHEMBL4641630 0.83 SMN1; SMN2 (0.50) L3MBTL1LMNAEPHX2NR1H4SMN1; SMN2
SCHEMBL13624072 0.83 HTT (0.43) HTTL3MBTL1KDM4ELMNAALDH1A1
SCHEMBL28514869 0.80 KDM4E (0.43) HTTKDM4EALDH1A1KMT2AEPHX2
SCHEMBL4641997 0.80 ELANE (0.46) HTTL3MBTL1KDM4ELMNAALDH1A1
SCHEMBL14502009 0.79 GAA (0.46) KDM4ELMNAALDH1A1GAAKMT2A
SCHEMBL4641910 0.78 RBP4 (0.41)
SCHEMBL13624065 0.77 MAPK1 (0.41) HTTL3MBTL1KDM4ELMNAALDH1A1
SCHEMBL4640606 0.77 ALDH1A1 (0.43) HTTL3MBTL1KDM4ELMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1824837-B1 SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS PFIZER (US) 2008-08-13 EP disclosed
EP-1824837-A1 SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS Pfizer, Inc. (US) 2007-08-29 EP disclosed
US-7214824-B2 Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists PFIZER INC. (US) 2007-05-08 US disclosed
WO-2006051378-A1 SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS PFIZER JAPAN INC. (JP) 2006-05-18 WO disclosed
US-20060100460-A1 Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists PFIZER, INC. 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100460-A1 Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists CNR1, AVPR1A, OPRL1 HTT 1890/4885L3MBTL1 1969/4885KDM4E 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.